CNS Drugs

, Volume 28, Issue 6, pp 513–518 | Cite as

Changes in Gait Variability with Anti-dementia Drugs: A Systematic Review and Meta-analysis

  • O. Beauchet
  • C. P. Launay
  • G. Allali
  • C. Annweiler
Systematic Review

Abstract

Background

Studies have examined the effects of anti-dementia drugs on gait performance. No structured critical evaluation of these studies has been done so far. The objectives of this study were (1) to perform a qualitative analysis of all published studies on changes in stride time variability (STV) with anti-dementia drugs among patients with Alzheimer disease through a systematic review, and (2) to quantitatively synthesize anti-dementia drug-related changes in STV.

Methods

An English and French MEDLINE search was conducted on November 2013, with no limit of date, using the Medical Subject Headings term “pharmaceutical preparations” combined with “delirium”, “dementia”, “amnestic”, “cognitive disorders” AND “gait” OR “gait disorders, neurologic” OR “gait apraxia”. Fixed-effects meta-analyses were performed to compare STV before and after the use of anti-dementia drugs, and to compare the final STV among participants in intervention and control groups.

Results

Of the 110 originally identified abstracts, four studies (i.e., one assessing galantamine, one donepezil, one memantine, and one memantine and acetylcholinesterase inhibitors) were included in the qualitative review, and three studies in the quantitative synthesis. Results were mixed, as two studies showed significant between-visit improvements (i.e., decrease in mean value) in STV, while one study did not, and the last one reported mixed results. In the meta-analysis, there was no difference between intervention and control groups (summary mean difference of final STV = −0.38 % [95 % confidence interval −1.14 to 0.37]) and no before–after difference in the intervention group (summary mean difference of STV = 0.66 [95 % confidence interval −0.17 to 1.49]).

Conclusions

Our findings showed inconclusive effects of anti-dementia drugs on STV.

References

  1. 1.
    Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012;60:2127–36.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F. Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat. 2008;4:155–60.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Allan LM, Ballard CG, Burn DJ, Kenny RA. Prevalence and severity of gait disorders in Alzheimer’s and non-Alzheimer’s dementias. J Am Geriatr Soc. 2005;53:1681–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Beauchet O, Allali G, Annweiler C, Bridenbaugh S, Assal F, Kressig RW, Herrmann FR. Gait variability among healthy adults: low and high stride-to-stride variability are both a reflection of gait stability. Gerontology. 2009;55:702–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Allali G, Kressig RW, Assal F, Herrmann FR, Dubost V, Beauchet O. Changes in gait while backward counting in demented older adults with frontal lobe dysfunction. Gait Posture. 2007;26:572–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Beauchet O, Allali G, Launay C, Herrmann FR, Annweiler C. Gait variability at fast-pace walking speed: a biomarker of mild cognitive impairment? J Nutr Health Aging. 2013;17:235–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Hausdorff JM, Rios DA, Eldelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil. 2001;82:1050–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Maki BE. Gait changes in older adults: predictors of falls or indicators of fear? J Am Geriatr Soc. 1997;45:313–20.PubMedGoogle Scholar
  9. 9.
    Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer’s disease. J Am Geriatr Soc. 2008;56:946–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;57:359–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Beauchet O, Allali G, Launay C, Fantino B, Annweiler C. Does memantine improve the gait of individuals with Alzheimer’s disease? J Am Geriatr Soc. 2011;59:2181–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Beauchet O, Launay C, Allali G, Watfa G, Gallouj K, Herrmann F, Annweiler C. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurol. 2013;13:184.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol. 2009;9:42.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.CrossRefGoogle Scholar
  15. 15.
    Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolf FM. Meta-analysis: quantitative methods for research synthesis. Beverly Hills: Sage; 1986.Google Scholar
  18. 18.
    McKeage K. Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs. 2009;23:881–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Tsuno N. Donepezil in the treatment of patients with Alzheimer’s disease. Expert Rev Neurother. 2009;9:591–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer’s disease: an update. Clin Interv Aging. 2007;2:17–32.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Almeida QJ, Frank JS, Roy EA, Patla AE, Jog MS. Dopaminergic modulation of timing control and variability in the gait of Parkinson’s disease. Mov Disord. 2007;22:1735–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699–723.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • O. Beauchet
    • 1
  • C. P. Launay
    • 1
  • G. Allali
    • 2
  • C. Annweiler
    • 1
    • 3
  1. 1.Division of Geriatric Medicine, Department of NeuroscienceUPRES EA 4638, UNAM, Angers University HospitalAngers Cedex 9France
  2. 2.Department of NeurologyGeneva University Hospital and University of GenevaGenevaSwitzerland
  3. 3.Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and DentistryThe University of Western OntarioLondonCanada

Personalised recommendations